Management of ongoing direct anticoagulant treatment in patients with hip fracture

Carlo Rostagno1,2,5*, Alessandro Cartei2, Gianluca Polidori2, Roberto Civinini4, Alice Ceccofoglio2, Gaia Rubbieri2, Massimo Curcio2, Alberto Boccaccini3, Adriano Peris4 & Domenico Prisco1

Aim of the present study was to investigate the effects of ongoing treatment with DOACs on time from trauma to surgery and on in-hospital clinical outcomes (blood losses, need for transfusion, mortality) in patients with hip fracture. Moreover we evaluated the adherence to current guidelines regarding the time from last drug intake and surgery. In this observational retrospective study clinical records of patients admitted for hip fracture from January 2016 to January 2019 were reviewed. 74 patients were in treatment with DOACs at hospital admission. Demographic data, comorbidities and functional status before trauma were retrieved. As control group we evaluated 206 patients not on anticoagulants matched for age, gender, type of fracture and ASA score. Time to surgery was significantly longer in patients treated with DOACs (3.6 ± 2.7 vs. 2.15 ± 1.07 days, p < 0.0001) and treatment within 48 h was 47% vs. 80% in control group (p < 0.0001). The adherence to guidelines’ suggested time from last drug intake to surgery was 46%. Neither anticipation nor delay in surgery did result in increased mortality, length of stay or complication rates with the exception of larger perioperative blood loss (Hb levels < 8 g/dl) in DOACs patients (34% vs 9% p < 0.0001). Present results suggest that time to surgery is significantly longer in DOAC patients in comparison to controls and adherence to guidelines still limited.

Hip fractures occur in about 18% of women and 6% of men in their ninth decade1,2. In the world the number of hip fractures is expected to increase from 1.26 million in 1990 to 4.5 million by the year 20503. Early surgery remains the mainstay of treatment in these patients4. Chronic oral anticoagulation, involving at least 15% of hip fracture population, has been reported to significantly increase time to surgery and length of hospital stay5–7. However, limited data exist about direct anticoagulant agents (DOACs) in this setting8–11. Aim of present study was to investigate the effects of ongoing treatment with DOACs on time to surgery and clinical outcomes in patients with hip fracture. Moreover we evaluated the adherence to guideline’s suggested time to surgery in relation to the last drug intake12,13.

Methods

The study is part of a project of Italian Health Ministry and Regione Toscana—RF-2010-2316600—and was approved by Ethical Committee of Regione Toscana. All patients and/or their legal guardians gave written informed consent to treatment and collection of clinical data for research purposes at admission. All research was performed in accordance with relevant guidelines/regulations. Aim of this observational retrospective study was to evaluate the effects of ongoing treatment with DOACs at the moment of trauma on time to surgery and on in hospital clinical outcomes (blood losses, need for transfusion, mortality) in elderly patients with hip fracture. Moreover we evaluated the adherence to current guidelines regarding the time from last drug intake and surgery. The clinical records of patients admitted for hip fracture in the period January 2016–January 2019 to a single tertiary teaching trauma center in Italy were reviewed. Patients were treated by a multidisciplinary team according to a previously described model14. From the records all the patients in treatment with a DOACs (Dabigatran Etxilate, Rivaroxaban, Apixaban, Edoxaban) at hospital admission were extracted. Data from records of 206
patients referred for hip fracture but not on anticoagulants, matched for age, gender, type of fracture and ASA score were considered as control.

Data collection.  Demographic data, comorbidities, functional status before trauma and clinical outcome were recalled from clinical records. Age, sex, type and dose of DOACs, indication to treatment, time from the last drug intake, time to surgery, length of hospital stay, need for blood transfusion and postoperative complications were recorded. Laboratory data including blood cell count, PT- INR and aPTT, creatinine and troponin were recalled from electronic records. Creatinine clearance was calculated with the Cockroft-Gault formula.

Adherence to DOACs withdrawal guidelines.  We evaluated the adherence to suggested time from last intake to surgery, recalled from pharmacological reconciliation, according to EHRA guidelines and derived Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) cohort study criterions\(^\text{12,13}\). High risk elective surgery was allowed 48 h after the last administration for apixaban, edoxaban and rivaroxaban while in patients treated with dabigatran timing was related to renal function (expressed as creatinine clearance).

Statistical analysis.  Continuous variables were reported as mean and standard deviation. Non continuous variables were reported as frequency of distribution. Statistical analysis of continuous data was performed using non-parametric Mann–Whitney test while non continuous data were analyzed using Fisher’s exact test. A probability value of 0.05 was considered statically significant.

Results

Seventy-four consecutive patients in treatment with a DOACs at the moment of hospitalization for hip fracture were included in the study. Indication to anticoagulation and relative distribution of treatments are reported in Table 1. More than 90% of patients were under treatment for non-valvular atrial fibrillation. Dabigatran, apixaban and rivaroxaban had similar distribution while only 3 patients were in edoxaban.

Demographic and clinical characteristics of study and control group are reported in Table 2. Mean age was not statistically different (84 ± 5.4 years in DOACs patients vs 84.1 ± 8.5 years in controls). Similarly, no gender differences was found between the two groups (female sex was 68% in DOACs patients vs 76% in controls). Again there was no significant difference in type of fracture and surgical intervention between groups. The incidence of single comorbidities was not significantly different between the groups.

Time to surgery was significantly longer in patients treated with DOACs (Table 3). Actually, 46% of patients were treated within 48 h in comparison to 80% of those in the control group (p < 0.0001). No significant differences were found in hospital length of stay between the groups. There were no intraoperative complications, in particular no complications related to spinal anesthesia in DOACs patients. Post-operative complications are reported in Table 4.

Severe anemia, defined as post-operative Hb concentration < 8 g/dl was significantly more frequent in patients treated with DOACs than in controls although the number of patients undergoing red blood cell transfusion did not differ between groups. The hospital mortality was not different between the two groups. Finally we did not find any significant difference in bleeding related to surgery between dabigatran and direct factor Xa inhibitors (neither as post operative anemia nor as percentage of patients needing transfusions).

Adherence to present recommendations regarding time to surgery in patients on DOACs.  The adherence to EHRA guidelines and PAUSE cohort study criterions about time from the last drug intake to surgery was 46% (34/74 patients on DOACs) (Table 3). Surgery was performed earlier than suggested in 8 patients on dabigatran (7 had creatinine clearance between 30 and 50 ml/min and 1 < 30 ml/min) and in one patient in the other 3 drugs (all of them had creatinine clearance < 30 ml/min). In 2 patients on dabigatran, 6 on rivaroxaban and 5 on apixaban time to surgery was between 48 and 72 h. Ten, including the 2 on dabigatran, had a creatinine clearance > 50 ml/min. Finally 17 patients had a delay to surgery > 72 h not justified by a drug-related higher hemorrhagic risk. For 9 of them, for whom time to surgery exceeded 5 days, the delay was due to the need for clinical stabilization of concomitant comorbidities diagnosed at hospital admission (3 had pneumonia with

| Indication for anticoagulation | n | % |
|-------------------------------|---|---|
| Atrial fibrillation           | 68 | 91 |
| Venous thromboembolism        | 5  | 7  |
| Other                         | 1  | 2  |
| DOA                           |   |    |
| Dabigatran                    | 28 | 38 |
| Rivaroxaban                   | 19 | 26 |
| Apixaban                      | 24 | 32 |
| Edoxaban                      | 3  | 4  |

Table 1.  Indication for anticoagulant therapy and distribution of different DOAC among patients.
Table 2. Characteristics of DOACs patients and controls.

| Characteristic                  | DOA (74) | Controls (206) | p    |
|--------------------------------|----------|----------------|------|
| Mean age                       | 84 ± 5.4 | 84.1 ± 8.5     | ns   |
| Gender M/F                     | 24/50 (68%) | 49/157 (76.2%) | ns   |
| Type of fracture               |          |                |      |
| Neck fracture                  | 36       | 107            | ns   |
| Per trochanteric               | 36       | 93             | ns   |
| Subtrochanteric                | 2        | 6              | ns   |
| BADL ≤ 4                       | 21 (28%) | 50 (25%)       | ns   |
| Previous mobility              |          |                |      |
| > 50 m                         | 20       | 65             | ns   |
| ≤ 50 m                         | 29       | 74             | ns   |
| Home confined                  | 25       | 67             | ns   |
| ASA score                      |          |                |      |
| 3                              | 69       | 195            | ns   |
| 4                              | 5        | 11             |      |
| Comorbidities                  |          |                |      |
| Ischemic heart disease         | 12 (16%) | 31 (15%)       | ns   |
| Heart failure                  | 11 (14%) | 16 (8%)        |      |
| Chronic obstructive pulmonary disease | 6 (8%) | 27 (13%)    | ns   |
| Chronic renal failure          | 5 (6%)   | 14 (7%)        | ns   |
| Cancer                         | 6 (8%)   | 20 (5%)        | ns   |
| Dementia                       | 19 (25%) | 44 (21%)       | ns   |
| Hypertension                   | 44 (59%) | 141 (68%)      |      |
| Diabetes mellitus              | 17 (10%) | 37 (18%)       | ns   |
| Parkinson disease              | 4 (7.5%) | 19 (5%)        | ns   |
| More than two comorbidities    | 39 (52%) | 125 (60%)      | 0.036 |

Table 3. Comparison of mortality rate and hospitalization between patients taking anticoagulants and controls.

| Characteristic                  | DOA (74) | Controls (206) | p    |
|--------------------------------|----------|----------------|------|
| Time to surgery                | 3.6 ± 2.7 | 2.15 ± 1.07    | < 0.0001 |
| % treated < 48 h               | 47%      | 80%            | < 0.0001 |
| Length of hospitalization      | 14 ± 4.7 | 14.6 ± 5.6     | ns   |
| In-hospital mortality          | 1 (1.5%) | 9 (3.4%)       | ns   |

Table 4. Comparison of postoperative complications between patients taking anticoagulants and controls.

| Complication                    | DOA (74) | Controls (206) | p    |
|---------------------------------|----------|----------------|------|
| Anemia (Hb < 8.0 g/dl)         | 28 (37%) | 26 (12%)       | < 0.0001 |
| Red blood cell transfusion      | 46%      | 41%            | ns   |
| Respiratory failure             | 2 (3%)   | 8 (3.8%)       | ns   |
| Acute renal failure             | 2 (3%)   | 7 (3.3%)       | ns   |
| Pneumonia                       | 7 (9%)   | 6 (2.9%)       | ns   |
| Sepsis                          | 2 (3%)   | 3 (1.4%)       | ns   |
| Wound infection                 | 1 (1.3%) | 1 (0.3%)       | ns   |
| Pulmonary embolism              | 0 (0.6%) | 1 (0.3%)       | ns   |
| Deep vein thrombosis            | 4 (5.4%) | 18 (8.7%)      | ns   |
| Acute myocardial infarction     | 2 (3%)   | 3 (1.4%)       | ns   |
| Acute heart failure             | 5 (6.5%) | 7 (3.3%)       | ns   |
| Delirium                        | 18 (24%) | 35 (16.9%)     | ns   |
| Stroke                          | 0 (0%)   | 3 (1.4%)       | ns   |
respiratory failure, 1 urinary sepsis, 1 heart failure complicating myocardial infarction, 3 hyperkinetic delirium and 1 advanced neoplasm). In the other 8 patients delay was related to organization problems.

Neither anticipation nor delay in surgery did result in increased mortality or complication rates in comparison to control group.

### Discussion

Since their introduction in clinical practice DOACs progressively replaced antivitamin K for thromboembolic prophylaxis in particular in patients with non valvular atrial fibrillation. Ageing is related both to an increased need for non cardiac surgery and to an increased incidence of atrial fibrillation. Several suggestions for withdrawal of anticoagulant treatment have been proposed for elective surgery based essentially on the hemorrhagic risk related to surgical procedure and the value of creatinine clearance. EHRA guidelines suggest to refer to these indication also for time-dependent surgery.

Since about 15% of patients with hip fracture are in anticoagulant treatment at the moment of trauma, it may be estimated that in Italy at least 15,000 anticoagulated patients are annually admitted for hip fracture. Early surgery (usually within 48 h from trauma) is associated with a lower short and long-term mortality and to a better functional outcome. Perioperative hemorrhagic risk related to anticoagulation may significantly delay surgery and worsen prognosis.

Despite the clinical relevance, few studies investigated perioperative management of DOACs in hip fracture patients. In the study by Tran et al. 27 patients in treatment with DOACs were included. Time to surgery was significantly longer in these patients (average 66.9 h) in comparison to 233 patients treated with antivitamin K (average 36.4 h) and 260 not anticoagulated patients (26.2 h).

Similar results were reported by Razvan et al. Overall anticoagulated patients had a longer time to surgery and a longer length of stay (LOS) than control group. One hundred and forty of 229 anticoagulated patients were on warfarin, 46 on rivaroxaban, 10 on dabigatran and 33 on apixaban. Time to surgery in mean has been 28 h in patients on warfarin and between 9 and 20 h longer for DOAC.

Mullins et al. evaluated whether early surgery may be safely performed in patients in treatment with DOACs. Among 125 patients who underwent hip surgery 63 were on DOACs at admission (14 Apixaban, 5 Dabigatran e 44 Rivaroxaban). The end points of the study were surgical bleeding, need for transfusion, reinsertion rate and 30 day mortality. According to developed protocol, time to surgery did not differ between anticoagulated and control group (19.4 h) with 87% treated within 36 h. There was not significant difference in blood loss although the rate of transfusion was higher in DOAC patients (18 vs 10%). Reinsertion rate was also higher in anticoagulated patients (5% vs 0%). All cause mortality was 2% in DOAC patients and 8% in controls. The study has several limitations. First, the authors do not report specified transfusion criteria not allowing any comparison with the literature; second, postoperative hemoglobin was measured on the first postoperative day and not at the nadir that often occurs at day 2 to 5 after the operation. Finally, no detailed information is provided about anesthesiologic technique and comorbidities. A recent investigation clearly stated that in patients in DOACs neuraxial anesthesia was associated with a significant delay to hip surgery in comparison to general anesthesia.

A small pilot study evaluated the safety of DOACs in elderly patients with hip fracture. DOACs concentrations were measured at admission and before surgery. Time to surgery was ≥ 48 h from the last intake of drug in 7/11 patients and 5, all treated with apixaban, had still therapeutic concentrations of drugs at surgery. These results suggested a reduced drug elimination rate in elderly and may explain the significant higher fall in hemoglobin in patients on DOACs in comparison to patients on warfarin.

The results of present investigation confirm that in patients on treatment with DOACs at the time of trauma, surgery for hip fracture is delayed at least 24 h in comparison to non-anticoagulated patients. Only 48% patients were treated within 48 h in comparison to 80% of control group. However this delay is conceivable since almost all patients in our institution had hip surgery performed under neuraxial anesthesia. When we evaluated the adherence to guidelines suggesting time from last intake and surgery it was overall limited (46%). Surgery was performed earlier than suggested in 11% of patients. Most of these were subjects in dabigatran and with decreased creatinine clearance. Delay of surgery by 24 h in these patients should improve safety of neuraxial anesthesia and decrease the risk of bleeding. In theory with close adherence to guidelines, in our population 79% of patients might had surgery within 48 h from trauma. Nevertheless nine out of the 17 patients with surgery delayed > 72 h needed clinical stabilization before surgery. We did not find any significant difference in postoperative complications between patients in DOACs and control group.

Severe anemia (Hb < 8/dl) was significantly more frequent in DOACs patients. Surgery performed earlier than suggested (11% of patients) as well the persistence of therapeutic concentrations of DOACs in about 50% of patients treated within 48 h, as suggested by the paper of Viktil et al., may be responsible for increased

### Table 5. Adherence to EHRA guidelines and PAUSE suggestions. Bold values indicate patients in whom surgery timing agreed to guidelines.

| Creatinine clearance | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
|----------------------|------------|-------------|----------|----------|
| > 50 ml/min          | 9          | 2           | 4        | 3        |
| 30–50 ml/min         | 7          | 4           | 0        | 3        |
| < 30 ml/min          | 1          | 0           | 2        | 1        |

https://doi.org/10.1038/s41598-021-89077-8
perioperative blood loss. Although we did not have any anesthesiologic complication, therapeutic DOACs concentrations may carry an higher risk in patients undergoing neuraxial anhestesia.

Limitations

The observational retrospective design is the main limitation of the study. Moreover the number of patients included is relatively small, although higher than in all the previous investigations, thus not allowing definite conclusions. Although indication to transfusion in our center is a fall in Hb below 8.0 g/dl, the decision to transfuse in frail patients is discretionally left to the clinician and this may account for the absence of significant differences in transfusion rate between DOACs patients and controls despite the difference in severe anemia found between groups. Anyway, the observational nature of the study offers the advantage of describing a real-world behavior.

Conclusions

Time to surgery is significantly longer in DOACs patients in comparison to controls and adherence to guidelines still limited, less that 50%. Nevertheless, we did not find any significant difference in clinical outcomes (death, length of stay, complication rate) between anticoagulated and not anticoagulated patients with the exception of a larger perioperative blood loss in DOACs patients. Further studies evaluating DOACs concentrations before surgery may allow to suggest ideal timing of surgery and proper anesthesiologic strategy.

Received: 29 May 2020; Accepted: 19 April 2021
Published online: 04 May 2021

References

1. Kim, S. H., Meehan, J. P., Blumenfeld, T. & Szabo, R. M. Hip fractures in the United States: 2008 nationwide emergency department sample. Arthritis Care Res. 64, 751–757 (2012).
2. Haentjens, P. et al. Meta-analysis: Excess mortality after hip fracture among older women and men. Ann. Intern. Med. 152(6), 380–390 (2010).
3. Veronese, N. & Maggi, S. Epidemiology and social costs of hip fracture. Injury 49, 1458–1460 (2018).
4. Moja, L. et al. Timing matters in hip fracture surgery: Patients operated within 48 hours have better outcomes. A meta-analysis and meta-regression of over 190,000 patients. PLoS ONE 7, e46175 (2012).
5. Eardley, W. G., Macleod, K. E., Freeman, H. & Tate, A. “Tiers of Delay”: Warfarin, hip fractures, and target-driven care. Geriatri. Orthop. Surg. Rehabil. 5(3), 103–108 (2014).
6. Aziz, S., Almeida, K. & Taylor, G. How should we manage hip fracture patients on direct oral anticoagulants? BMJ Evid Based Med. 26, 22–23 (2020) (published online ahead of print, 2020 Apr 24).
7. Lawrence, J. E., Fountain, D. M., Cundall-Curry, D. J. & Carrothers, A. D. Do patients taking warfarin experience delays to theatre, longer hospital stay, and poorer survival after hip fracture? Clin. Orthop. Relat. Res. 475(1), 273–279 (2017).
8. Tran, T. et al. The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. Thromb. Res. 136(5), 962–965 (2015).
9. Taranu, R. et al. Use of anticoagulants remains a significant threat to timely hip fracture surgery. Geriatri. Orthop. Surg. Rehabil. 9, 1–6 (2018).
10. Mullins, B. et al. Should surgery be delayed in patients taking direct oral anticoagulants who suffer a hip fracture? A retrospective, case-controlled observational study at a UK major trauma centre. BMJ Open 8, e020625. https://doi.org/10.1136/bmjopen-2017-020625 (2018).
11. Leer-Salvesen S, Dybvik E, Ranhoff AH, Husebø BL, Dahl OE, Engesæter LB, Gjertsen JE. Do direct oral anticoagulants (DOACs) cause delayed surgery, longer length of hospital stay, and poorer outcome for hip fracture patients? Eur Geriatr Med. 11(4):563-569. https://doi.org/10.1111/ege.12399 (2020).
12. Steffel, J. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 39(16), 1330–1393 (2018).
13. Douketis, J. D. et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern. Med. 179(11), 1469–1478 (2019) (published online ahead of print, 2019 Aug 5).
14. Rostagno, C. et al. In hospital and 3-month mortality and functional recovery rate in patients treated for hip fracture by a multidisciplinary team. PLoS ONE 11(7), e0158607 (2016).
15. Dentali, F. et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and metaanalysis of the literature. Circulation 126(20), 2381–2391 (2012).
16. Dobesh, P. P. & Fanikos, J. Direct oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation: Understanding differences and similarities. Drugs 75, 1627–1644 (2015).
17. Etzioni, D. A., Liu, J. H., Maggard, M. A. & Ko, C. Y. The aging population and its impact on the surgery workforce. Ann. Surg. 238, 170–177 (2003).
18. Partridge, I. S., Harari, D. & Dhesi, J. K. Frailty in the older surgical patient: A review. Age Ageing 41, 142–147. https://doi.org/10.1093/ageing/afr182 (2012).
19. Lai, A. N., Davidson, S., Galloway, W. & Thachil, J. Perioperative management of patients on new oral anticoagulants. Br. J. Surg. 101, 742–749. https://doi.org/10.1002/bjs.9405 (2014).
20. Beyer-Westendorf, J. et al. Peri-interventional management of novel oral anticoagulants in daily care results from the prospective Dresden NOAC registry. Eur. Heart J. 35, 1888–1896 (2014).
21. Ho, C.-A., Li, C.-Y., Hsieh, K.-S. & Chen, H.-F. Factors determining the 1-year survival after operated hip fracture: A hospital-based analysis. J. Orthop. Sci. 15, 30–37 (2010).
22. Bhandari, M. & Swiontkowski, M. Management of acute hip fracture. N. Engl. J. Med. 377(21), 2053–2062 (2017).
23. Vikil, K., Lehe, I., Ranhoff, A. H. & Molden, E. Serum concentrations and elimination rates of direct-acting oral anticoagulants (DOACs) in older hip fracture patients hospitalized for surgery: A pilot study. Drugs Aging 36, 65. https://doi.org/10.1007/s40266-018-0609-4 (2019).

Author contributions

C.R., A.B., A.P., D.P. wrote the manuscript test. G.R., M.C., A.C., R.C. retrieved and analyzed data. G.P. prepared tables. A.Cc. revised the text. All authors reviewed the manuscript.
Funding
This work is part of a project of Italian Health Ministry and Regione Toscana RF-2010-2316600.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to C.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021